Tifuvirtide Uses, Dosage, Side Effects and more
Tifuvirtide is the first members of a new class of anti-HIV drugs which is also called fusion inhibitors. It has received fast track designation from the FDA and is in Phase I/II clinical testing.
| Trade Name | Tifuvirtide |
| Generic | Tifuvirtide |
| Tifuvirtide Other Names | Peptide T1249, Tifuvirtide |
| Type | |
| Formula | C235H341N57O67 |
| Weight | Average: 5036.5637 Monoisotopic: 5033.502833871 |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
Uses
Investigated for use/treatment in acquired immune deficiency syndrome (AIDS) and aids-related infections and HIV infection.
How Tifuvirtide works
Tifuvirtide binds to a slightly different region of the HIV virus than Fuzeon (enfuvirtide). As a result,it exhibits activity against Fuzeon-resistant viruses. Tifuvirtide is designed to block fusion of HIV with host cells before the virus enters the cell and begins its replication process.
